Abstract
Objective
Breast cancer (BC) has a poor prognosis due to metastasis and recurrence. LINC01158 is aberrantly expressed in breast cancer. Therefore, we investigated the regulatory mechanism and prognostic value of LINC01158 in BC.
Methods
121 patients with BC were enrolled. LINC01158 and miR-711 levels were analyzed by RT-qPCR. Independent predictors of poor BC prognosis were analyzed by multifactorial Cox regression. Kaplan-Meier curves were used to analyze the 5-year survival rate of BC patients. DLR assay verified the relationship between LINC01158 and miR-711 target binding. CCK-8 was used to detect the proliferative capacity of cells. Transwell was used to analyze cell migration and invasion ability.
Results
In BC tissues and cell lines, LINC01158 expression was reduced and miR-711 levels were elevated. Low expression of LINC01158 resulted in a shortened overall survival of BC patients. LINC01158 binds to the miR-711 target and negatively correlates with the level of miR-711. Overexpression of LINC01158 decreased miR-711 levels and reduced BC cell proliferation, migration and invasion. In addition, Cox regression results showed that LINC01158 was an independent prognostic factor for BC.
Conclusion
LINC01158 may be a prognostic marker for BC. Increasing the expression level of LINC01158 could reduce the expression of miR-711, which could inhibit cell proliferation, migration and invasive behaviors, and has the potential to delay the progression of BC.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer





